APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL

DSpace/Manakin Repository

APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL

Citable link to this page

 

 
Title: APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL
Author: Li, Z; Abraham, B J; Berezovskaya, A; Farah, N; Liu, Y; Leon, T; Fielding, A; Tan, S H; Sanda, T; Weintraub, A S; Li, B; Shen, S; Zhang, J; Mansour, M R; Young, R A; Look, A T

Note: Order does not necessarily reflect citation order of authors.

Citation: Li, Z., B. J. Abraham, A. Berezovskaya, N. Farah, Y. Liu, T. Leon, A. Fielding, et al. 2017. “APOBEC signature mutation generates an oncogenic enhancer that drives LMO1 expression in T-ALL.” Leukemia 31 (10): 2057-2064. doi:10.1038/leu.2017.75. http://dx.doi.org/10.1038/leu.2017.75.
Full Text & Related Files:
Abstract: Oncogenic driver mutations are those that provide a proliferative or survival advantage to neoplastic cells, resulting in clonal selection. Although most cancer-causing mutations have been detected in the protein-coding regions of the cancer genome; driver mutations have recently also been discovered within noncoding genomic sequences. Thus, a current challenge is to gain precise understanding of how these unique genomic elements function in cancer pathogenesis, while clarifying mechanisms of gene regulation and identifying new targets for therapeutic intervention. Here we report a C-to-T single nucleotide transition that occurs as a somatic mutation in noncoding sequences 4 kb upstream of the transcriptional start site of the LMO1 oncogene in primary samples from patients with T-cell acute lymphoblastic leukaemia. This single nucleotide alteration conforms to an APOBEC-like cytidine deaminase mutational signature, and generates a new binding site for the MYB transcription factor, leading to the formation of an aberrant transcriptional enhancer complex that drives high levels of expression of the LMO1 oncogene. Since APOBEC-signature mutations are common in a broad spectrum of human cancers, we suggest that noncoding nucleotide transitions such as the one described here may activate potent oncogenic enhancers not only in T-lymphoid cells but in other cell lineages as well.
Published Version: doi:10.1038/leu.2017.75
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5629363/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492310
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters